Polycythemia Vera Market Expands as FDA Fast Tracks New Treatments and Clinical Trials Show Promising Results
DelveInsight's report, titled ' Polycythemia Vera Market Insight, Epidemiology and Market Forecast -2034 ', provides a detailed assessment of historical and projected market trends from 2020 to 2034. The analysis encompasses epidemiology segmentation, treatment paradigms, emerging therapies, and competitive dynamics, offering stakeholders actionable insights into market opportunities and challenges. The report highlights how the anticipated introduction of targeted therapies and improved diagnostic tools will reshape the PV treatment landscape over the next decade.
In 2024, the United States dominated the Polycythemia market, accounting for over 75% of the total market size, which amounts to USD 1.9 Billion across the 7MM. Among EU4 countries, Germany accounts for the maximum market size, while the United Kingdom occupies the bottom of the ladder in 2024. This trend is expected to continue reflecting disparities in treatment accessibility, Polycythemia Vera prevalence, and diagnostic rates across regions.
Download the report to understand which factors are driving the Polycythemia Vera therapeutic market @ Polycythemia Vera Market Trends.
The report also provides historical as well as forecasted PV epidemiology segmented by Total Prevalent Population of Polycythemia Vera, Prevalent Population of Polycythemia Vera Based on Symptoms, Gender-specific Prevalence of Polycythemia Vera, Prevalence of Polycythemia Vera by Gene Mutation, Prevalence of Polycythemia Vera Based on Risk, and Age-specific Prevalence of Polycythemia Vera in the 7MM.
The report estimates that the 7MM had approximately 320,000 Polycythemia Vera cases in 2024, with numbers expected to rise steadily during the forecast period. Gender-specific data indicates that approximately 56% of the patient share in 7MM is attributed to males, whereas 44% are females. Additionally, across all races and ethnicities, the PV incidence is about 2.8 per 100,000 men and roughly 1.3 per 100,000 women.
Discover evolving trends in Polycythemia Vera patient pool forecasts @ Polycythemia Vera Epidemiology Analysis.
Recent Developments:
In the latest financial statement, Incyte reported strong growth for Jakafi with net revenues of $773 million in Q4 2024 and $2.79 billion for the full year.
In March 2025, Protagonist Therapeutics and Takeda announced positive topline results from the Phase 3 VERIFY study, where rusfertide met its primary and all secondary endpoints in treating polycythemia vera. These recent developments indicate positive momentum in the Polycythemia Vera treatment market.
Rusfertide achieved a major milestone with the presentation of Phase 3 VERIFY trial results at the ASCO Annual Meeting in June 2025. The study met its primary endpoint and all key secondary endpoints, showing that rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups compared to placebo.
In May 2025, the FDA granted Fast Track designation to givinostat, an orally administered histone deacetylase (HDAC) inhibitor for treating patients with polycythemia vera, highlighting givinostat's potential to make a meaningful difference.
Learn more about the evolving trends in the Polycythemia Vera treatment market @ Polycythemia Vera Recent Developments.
Polycythemia Vera management currently relies on a combination of treatments, including phlebotomy, cytoreductive agents such as hydroxyurea, and JAK inhibitors like JAKAFI (RUXOLITINIB) from Incyte/Novartis. Other notable medications used in the management of PV include BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals) and PEGASYS (pharmaand GmbH). Given its very different MoA compared to JAKAFI and BESREMi, rusfertide could become a viable alternative as an earlier line of therapy. In 2024, JAKAFI generated the highest revenue among these Polycythemia Vera therapies.
While these therapies help manage symptoms and reduce thrombotic risks, they are associated with limitations including drug resistance, long-term toxicity, and inadequate control of disease progression. DelveInsight's report emphasizes that a significant number of patients experience suboptimal responses to existing treatments, highlighting a pressing need for novel mechanisms of action.
The report highlights that the Polycythemia Vera pipeline features several investigational therapies across phases of development. Notable candidates include DIVESIRAN (Silence Therapeutics), PPMX-T003 (Perseus Proteomics), NAVITOCLAX (AbbVie), VAC85135 (Johnson & Johnson), 9MW3011/DISC-3405 (Mabwell), GLB-001 (GluBio Therapeutic) and others.
Despite progress, challenges such as delayed diagnosis, treatment-related anemia, and lack of consensus on optimal monitoring strategies persist. DelveInsight's analysis identifies biomarker development and patient-centric drug delivery systems as key areas for innovation.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Polycythemia Vera Market Overview at a Glance
5. Epidemiology and Market Forecast Methodology
6. Key Events
7. Polycythemia Vera Background and Overview
8. Polycythemia Vera Treatment
9. Polycythemia Vera Epidemiology and Patient Population in the 7MM
10. Polycythemia Vera Patient Journey
11. Polycythemia Vera Marketed Drug
12. Polycythemia Vera Emerging Drugs
13. Polycythemia Vera: 7MM Analysis
14. Unmet needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports
Polycythemia Vera Pipeline Insight
Polycythemia Vera Pipeline Insight provides comprehensive insights about the Polycythemia Vera pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Polycythemia Vera companies, including Silence Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, and Disc Medicine among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
13 minutes ago
- Globe and Mail
If You Bought 100 Shares of IonQ at Its IPO, Here's How Much Money You'd Have Now
Key Points IonQ began trading on public markets in 2021 after merging with a special purpose acquisition company. Shares of IonQ have soared over the past four years. The stock has plenty of potential to continue rising as the quantum computing industry matures. 10 stocks we like better than IonQ › With the potential to revolutionize computing as we know it, quantum computing has soared in popularity among investors seeking tech stocks with ample growth opportunity. Of the limited number of quantum computing stocks, IonQ (NYSE: IONQ), a leader in the field, is one of the most recognizable names. But a stock growing in popularity doesn't always ensure that shares will also rise. Let's see how IonQ investors who bought shares four years ago after the company's debut on public markets have fared. The first quantum computing company on the scene Proclaiming itself the "first publicly traded, pure-play quantum computing company," IonQ began trading on Oct. 1, 2021 at $10.60 after the company completed a merger with a special purpose acquisition company (SPAC). Over the following years, the company has announced several notable achievements. From opening the first quantum computing manufacturing facility in the United States, to applying quantum computing to artificial intelligence (AI) and machine learning that advances hybrid quantum-classical computing to improve both large language models and generative AI, IonQ has made tremendous strides that have excited investors' interest. As a result of the company's progress, shares of IonQ have soared. People who invested $1,060 to buy 100 shares at the stock's open on the first day of trading at it's opening price had seen their positions grow to $4,122 as of the end of trading on Aug. 6, 2025. Is it a quantum leap to think that IonQ stock can rise further? As a leader in the burgeoning quantum computing field, IonQ stock is one of the most common considerations for investors seeking exposure to the cutting-edge technology. While quantum computing might seem the stuff of science fiction, the company is demonstrating that there's nothing fictitious about the technology. As it pursues integrating its technology with hyperscalers like Microsoft Azure and Amazon Web Services, the company has robust growth potential over the coming years, and there's the definite potential for IonQ stock to continuing surging higher. Should you invest $1,000 in IonQ right now? Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $619,036!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,092,648!* Now, it's worth noting Stock Advisor's total average return is 1,026% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
Edmonton Journal
2 hours ago
- Edmonton Journal
‘He's not waiting until 2026': Trump likely to reopen CUSMA trade pact in the fall, Doug Ford warns
Article content OTTAWA — Ontario Premier Doug Ford is warning that U.S. President Donald Trump could choose to suddenly 'pull the carpet out from underneath us' by opening up the trade agreement his administration negotiated with Canada during his first term. Article content He said Ottawa needs to prepare for that to happen this fall. Article content Article content Ford made the comments after the country's premiers and Prime Minister Mark Carney met in private for the first time since Trump escalated his trade war by hitting Canada with a baseline 35 per cent tariff last week. Article content Article content The new tariff, which took effect on Friday after the two countries failed to hit an Aug. 1 deadline to secure a new trade agreement, applies only to goods not covered by the Canada-United States-Mexico agreement on free trade, better known as CUSMA. Article content Article content 'He's not waiting until 2026. At any given time, President Trump — not that he even follows the rules — he can pull the carpet out from underneath us on CUSMA tomorrow with one signature,' Ford told reporters at Queen's Park in Toronto Wednesday afternoon as he called for swift action to bolster the economy. Article content 'So let's be prepared. I think it'll be coming in November. He's going to come at us with double barrels, so we better be ready and throw everything and the kitchen sink at this.' Article content Ontario is at odds with Saskatchewan over Canada's response to the escalating trade war. Ford has called for immediate retaliation, while Saskatchewan Premier Scott Moe is urging Ottawa to dial down its retaliatory tariffs. Article content Article content 'Maybe it's time for Canada even to at least not add additional counter-tariffs in this space, but to even consider removing some of the counter-tariffs that are harmful to Canadian businesses and Saskatchewan businesses today,' Moe said during a radio interview earlier Wednesday, adding the country is currently largely 'protected' under the CUSMA trade pact. Article content Article content Ahead of the meeting with Carney, Ford said he's frustrated by the impacts of high U.S. tariffs on his province's economy and called again for retaliatory tariffs. Article content 'You can't have tariffs on one side and not the other. I still stand by what I say — dollar for dollar, tariff for tariff. They understand strength, not weakness, and we should never, ever roll over and be weak,' Ford told reporters at a news conference Wednesday in Thornhill, Ont. Article content Ford said he told Carney and the premiers that if Ottawa chooses not to hike tariffs in its response, the threshold at which steel products become subject to tariffs should be lowered.
Vancouver Sun
2 hours ago
- Vancouver Sun
‘He's not waiting until 2026': Trump likely to reopen CUSMA trade pact in the fall, Doug Ford warns
OTTAWA — Ontario Premier Doug Ford is warning that U.S. President Donald Trump could choose to suddenly 'pull the carpet out from underneath us' by opening up the trade agreement his administration negotiated with Canada during his first term. He said Ottawa needs to prepare for that to happen this fall. Ford made the comments after the country's premiers and Prime Minister Mark Carney met in private for the first time since Trump escalated his trade war by hitting Canada with a baseline 35 per cent tariff last week. The new tariff, which took effect on Friday after the two countries failed to hit an Aug. 1 deadline to secure a new trade agreement, applies only to goods not covered by the Canada-United States-Mexico agreement on free trade, better known as CUSMA. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Ford said Trump likely won't wait for the scheduled review of the agreement next year. 'He's not waiting until 2026. At any given time, President Trump — not that he even follows the rules — he can pull the carpet out from underneath us on CUSMA tomorrow with one signature,' Ford told reporters at Queen's Park in Toronto Wednesday afternoon as he called for swift action to bolster the economy. 'So let's be prepared. I think it'll be coming in November. He's going to come at us with double barrels, so we better be ready and throw everything and the kitchen sink at this.' Ontario is at odds with Saskatchewan over Canada's response to the escalating trade war. Ford has called for immediate retaliation, while Saskatchewan Premier Scott Moe is urging Ottawa to dial down its retaliatory tariffs. 'Maybe it's time for Canada even to at least not add additional counter-tariffs in this space, but to even consider removing some of the counter-tariffs that are harmful to Canadian businesses and Saskatchewan businesses today,' Moe said during a radio interview earlier Wednesday, adding the country is currently largely 'protected' under the CUSMA trade pact. Ahead of the meeting with Carney, Ford said he's frustrated by the impacts of high U.S. tariffs on his province's economy and called again for retaliatory tariffs. 'You can't have tariffs on one side and not the other. I still stand by what I say — dollar for dollar, tariff for tariff. They understand strength, not weakness, and we should never, ever roll over and be weak,' Ford told reporters at a news conference Wednesday in Thornhill, Ont. Ford said he told Carney and the premiers that if Ottawa chooses not to hike tariffs in its response, the threshold at which steel products become subject to tariffs should be lowered. 'If people are concerned about hitting back, well, then there's the other alternative. Let's lower the quota for companies. When they come in, they get tariffs immediately,' Ford said following the meeting with Carney. Moe said his province is working to protect industries that are being hit hard by tariffs, including the steel sector. 'What we've done is pull forward a significant amount — 10 years, actually — of Crown procurement to support the steel industries here in Saskatchewan,' he said. Moe gave credit to Carney for his government's efforts to strengthen trade ties with other countries, including Mexico, particularly while Canada remains subject to China's canola oil and meal tariffs. When asked to explain why his government ended up putting American liquor back on the shelves and returning to its standard procurement processes, Moe said the government already prioritizes Saskatchewan companies. 'We need to get to that space in a more solid form with our largest trading partner, the United States of America, and someone is going to have to take the early steps,' he said, noting Alberta has also shifted its policies. Alberta Premier Danielle Smith's office said she would not be issuing any statements ahead of the meeting. Ford also called for large industrial projects that could lift national morale and make use of Canadian steel, something on the scale of building 'an aircraft carrier.' He called on Ottawa to cut taxes and said the Bank of Canada should drop its interest rate. 'We have to get the governor of the Bank of Canada to lower those damn interest rates from 2.75,' he said. 'Knock 'em down. Build confidence. 'Let's work together on getting rid of the HST on homebuyers, and not just first (time) ones. Let's stimulate the market and we'll follow suit if the federal government does that.' Ford also said Wednesday he had a 'good conversation' with U.S. Commerce Secretary Howard Lutnick on Tuesday that was 'positive,' and he believes the 'prime minister is doing everything in his power to get a fair trade deal with the U.S.' Carney, who did not make himself available to media Wednesday, told a press conference in B.C. on Tuesday that he has not talked to Trump in recent days but would speak with him 'when it makes sense.' The prime minister added about 85 per cent of trade with the U.S. remains tariff-free because of CUSMA. Sector-specific tariffs, like the 50 per cent duty on steel, aluminum and copper, remain in place. Carney also suggested he may lift counter-tariffs if that helps Canada in the ongoing trade dispute. 'We look at what we can do for our industry that's most effective. In some cases, that will be to remove tariffs,' he said Tuesday. Foreign Affairs Minister Anita Anand and Finance Minister Francois-Philippe Champagne were in Mexico City on Wednesday, part of a two-day mission to meet with Mexican officials and businesses on trade. The Opposition Conservatives are fundraising off Carney's response to the escalating trade war. 'He ran his entire campaign on elbows up,' said a Tory fundraising email Wednesday. 'But his elbows dropped faster than temperatures in a Canadian winter while Trump put tariffs up.' — With files from David Baxter, Lisa Johnson and Allison Jones Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our politics newsletter, First Reading, here .
